Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trialResearch in context

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trialResearch in context

Summary: Background: Concerns remain over the long-term safety of vascular endothelial growth factor (VEGF) inhibitors to treat retinopathy of prematurity (ROP). RAINBOW is an open label randomised trial comparing intravitreal ranibizumab (in 0.2 mg and 0.1 mg doses) with laser therapy in very low...

Full description

Bibliographic Details
Main Authors: Neil Marlow, James D. Reynolds, Domenico Lepore, Alistair R. Fielder, Andreas Stahl, Han Hao, Annemarie Weisberger, Amit Lodha, Brian W. Fleck
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:EClinicalMedicine
Subjects:
Infant
Preterm
Retinopathy of prematurity
Anti-VEGF treatment
Randomised controlled trial
Neurodevelopment
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024001469

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024001469

Similar Items